## Congress of the United States House of Representatives

Washington, DC 20515

December 6, 2005

DEA Administrator Karen P. Tandy Drug Enforcement Administration Mailstop: AXS 2401 Jefferson Davis Highway Alexandria, VA 22301

Dear Administrator Tandy,

We are writing to express our strong support for the application from Professor Craker, of the University of Massachusetts-Amherst, for licensing as a bulk manufacturer of marijuana for distribution exclusively to federally-approved researchers. We believe DEA licensing of Prof. Craker's privately-funded facility would be in the public interest.

At present, the National Institute on Drug Abuse (NIDA) has an unjustifiable monopoly on the production of marijuana for legitimate medical and research purposes in the United States, grown under contract to NIDA at the University of Mississippi. Federal law clearly requires adequate competition in the manufacture of Schedule I and II substances. (See 21 U.S.C. § 823(a)(1); see also 21 C.F.R. § 1301.33(b).) The licensing of Prof. Craker's facility would provide privately-funded sponsors of FDA-approved research the necessary opportunity to conduct studies with a strain of marijuana of their own choosing, with immediate access to that strain for all FDA-approved studies and for possible prescription use. None of this is the case under NIDA's monopoly. Until an alternative source of supply is available, important privately-funded research into the therapeutic effects of marijuana for patients undergoing chemotherapy or suffering from AIDS, glaucoma, multiple sclerosis, or other diseases will not be initiated.

The University of Massachusetts-Amherst is one of the nation's distinguished research universities, and it is highly qualified to manufacture marijuana for legitimate medical and research purposes with effective controls against diversion. NIDA's monopoly makes very little sense given that the DEA has licensed privately-funded manufacturers of virtually all other Schedule I drugs, including LSD, MDMA (Ecstasy), and psilocybin.

As one of your predecessors, DEA Administrator Robert Bonner, stated, "Those who insist that marijuana has medical uses would serve society better by promoting or sponsoring more legitimate scientific research, rather than throwing their time, money and rhetoric into lobbying, public relations campaigns and perennial litigation." We urge you to grant Prof. Craker's application for registration as a bulk manufacturer so that such legitimate and privately-funded scientific research can be conducted.

Respectfully, John W. Olver Michael Capuano Member of Congress Member of Congress

Member of Congress

Tammy Baldwin Member of Congress

Ed Pastor Member of Congress

Dennis Kucinich

Member of Congress

Member of Congress

Member of Congress

Maurice Hinchey

Member of Congress

Member of Congress

Sheila Jackson-I

Member of Corgress

James P. McGovern Member of Congress

Raúl M. Hijalua Jun Member of Congress  Member of Congress  Jim McDermott Member of Congress
John Lewis Member of Congress  John Lewis Member of Congress
Jesse Jackson, Jr. Member of Congress  Member of Congress  Member of Congress
James Oberstar Member of Congress  Member of Congress
Carolyn Maloney Member of Congress  Lynn Cwoolsey Member of Congress
John F. Tierney Nember of Congress  John Conyers Member of Congress
Robert Wexler Member of Congress  Member of Congress
Martin Olav Sabo Member of Congress  Member of Congress  Member of Congress

David Price

David Price Member of Congress

Dana Rohrabacher Member of Congress

Robert E. Andrews Member of Congress

Edolphus Towns Member of Congress

Mike Honda Member of Congress Rosa DeLauro Member of Congress

Pete Stark Member of Congress

Sherrod Brown Member of Congress

Jim Moran Member of Congress

Jerrold Nadler Member of Congress

" is flere."

. ./.